[Abstract Only] Randomized Trial: Eplerenone Not Beneficial for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)

Commentary: Researchers find drug used widely to treat eye condition has ‘no benefit’ – University of Bristol (free)